| Ytd | -11.14% | |
| 1y | -18.92% |
| Open | 54.15 | Prev Close | 54.43 | Low | 54.15 | High | 55.45 | Mkt Cap | 2.58B |
| Vol | 120.67K | Avg Vol | 707.04K | EPS | 4.42 | P/E | 12.31 | Forward P/E | 10.92 |
| Beta | 0.34 | Short Ratio | 4.18 | Inst. Own | 113.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 12-27 | Earning | 08-06 | 50-d Avg | 48.54 | 200-d Avg | 57.79 | 1yr Est | 66.80 |
PBH News
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.98 per share, beating the
TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) toda
Bank of New York Mellon Corp cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:
Dimensional Fund Advisors LP increased its holdings in shares of Prestige Consumer Healthcare Inc. (
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quar
Fifth Third Bancorp boosted its position in Prestige Consumer Healthcare Inc. (NYSE: PBH) by 8,130.0
Bessemer Group Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE: PBH) by 20.9% du
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige
Investors need to pay close attention to PBH stock based on the movements in the options market late
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Pr
This under-the-radar healthcare stock just made its biggest acquisition ever -- and it could easily
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (th
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) s
SAN FRANCISCO, June 23, 2026 (GLOBE NEWSWIRE) -- Investors in Prestige Consumer Healthcare (NYSE: PB
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Pr
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is prepa
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
